Targeting Oxidant Stress as a Strategy for Preventing Vascular Complications of Diabetes and Metabolic Syndrome

Nutraceuticals, Glycemic Health and Type 2 Diabetes

Volumn , Issue , 2009, Pages 201-243

  McCarty, Mark F ^a   Inoguchi, Toyoshi ^b  

^a NutriGuard Research   (United States)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Benfotiamine nutritional supplement in Japan and United States; Endothelium dependent vasodilation; Gilbert syndrome; High dose thiamine therapy; Melatonin, regulating enzymes at transcriptional level; NO mediated vasodilation; Oxidant stress, mediating the macro and microvascular complications of diabetes; Plants and blue green algae, generating phycobilins; Spirulina protein; Taurine, modulating transmembrane calcium flux

Indexed keywords

EID: 84889342552     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780813804149.ch11     Document Type: Chapter

References (327)

1. Abebe W, Mozaffari MS. 2000. Effects of chronic taurine treatment on reactivity of the rat aorta. Amino Acids 19(3-4):615-623.
2. Aksoy N, Vural H, Sabuncu T, Aksoy S. 2003. Effects of melatonin on oxidativeantioxidative status of tissues in streptozotocin-induced diabetic rats. Cell Biochem Funct 21(2):121-125.
3. Ali SM, Chakraborty SK. 1989. Role of plasma ascorbate in diabetic microangiopathy. Bangladesh Med Res Counc Bull 15(2):47-59.
4. Alp NJ, Mussa S, Khoo J, Cai S, Guzik T, Jefferson A, Goh N, Rockett KA, Channon KM. 2003. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest 112(5):725-735.
5. Alvarado-Vasquez N, Lascurain R, Ceron E, Vanda B, Carvajal-Sandoval G, Tapia A, Guevara J, Montano LF, Zenteno E. 2006. Oral glycine administration attenuates diabetic complications in streptozotocin-induced diabetic rats. Life Sci 79(3):225-232.
6. Alvarado-Vasquez N, Zamudio P, Ceron E, Vanda B, Zenteno E, Carvajal-Sandoval G. 2003. Effect of glycine in streptozotocin-induced diabetic rats. Comp Biochem Physiol C Toxicol Pharmacol 134(4):521-527.
7. Anderson RA, Evans LM, Ellis GR, Khan N, Morris K, Jackson SK, Rees A, Lewis MJ, Frenneaux MP. 2006. Prolonged deterioration of endothelial dysfunction in response to postprandial lipaemia is attenuated by vitamin C in Type 2 diabetes. Diabet Med 23(3):258-264.
8. Antolin I, Rodriguez C, Sainz RM, Mayo JC, Uria H, Kotler ML, Rodriguez-Colunga MJ, Tolivia D, Menendez-Pelaez A. 1996. Neurohormone melatonin prevents cell damage: Effect on gene expression for antioxidant enzymes. FASEB J 10(8):882-890.
9. Antoniades C, Shirodaria C, Warrick N, Cai S, de BJ, Lee J, Leeson P, Neubauer S, Ratnatunga C, Pillai R, Refsum H, Channon KM. 2006. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 114(11):1193-1201.
10. Antoniades C, Tousoulis D, Tountas C, Tentolouris C, Toutouza M, Vasiliadou C, Tsioufis C, Toutouzas P, Stefanadis C. 2004. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: The effects of vitamin C. Diabet Med 21(6):552-558.
11. Anuradha CV, Balakrishnan SD. 1999. Taurine attenuates hypertension and improves insulin sensitivity in the fructose-fed rat, an animal model of insulin resistance. Can J Physiol Pharmacol JID - 0372712 77(10):749-754.
12. Anwar MM, Meki AR. 2003. Oxidative stress in streptozotocin-induced diabetic rats: Effects of garlic oil and melatonin. Comp Biochem Physiol A Mol Integr Physiol 135(4):539-547.
13. Azuma J, Sawamura A, Awata N. 1992. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J 56(1):95-99.
14. Azuma J, Sawamura A, Awata N, Ohta H, Hamaguchi T, Harada H, Takihara K, Hasegawa H, Yamagami T, Ishiyama T. 1985. Therapeutic effect of taurine in congestive heart failure: A double- blind crossover trial. Clin Cardiol 8(5):276-282.
15. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. 2003. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52(8):2110-2120.
16. Babu PV, Sabitha KE, Shyamaladevi CS. 2006a. Therapeutic effect of green tea extract on advanced glycation and cross-linking of collagen in the aorta of streptozotocin diabetic rats. Clin Exp Pharmacol Physiol 33(4):351-357.
17. Babu PV, Sabitha KE, Shyamaladevi CS. 2006b. Therapeutic effect of green tea extract on oxidative stress in aorta and heart of streptozotocin diabetic rats. Chem Biol Interact 162(2):114-120.
18. Baker TA, Milstien S, Katusic ZS. 2001. Effect of vitamin C on the availability of tetrahydrobiopterin in human endothelial cells. J Cardiovasc Pharmacol 37(3):333-338.
19. Baranano DE, Rao M, Ferris CD, Snyder SH. 2002. Biliverdin reductase: A major physiologic cytoprotectant. Proc Natl Acad Sci USA 99(25):16093-16098.
20. Barua M, Liu Y, Quinn MR. 2001. Taurine chloramine inhibits inducible nitric oxide synthase and TNF-alpha gene expression in activated alveolar macrophages: Decreased NF-kappaB activation and IkappaB kinase activity. J Immunol 167(4):2275-2281.
21. Basta G, Lazzerini G, Del Turco S, Ratto GM, Schmidt AM, De Caterina R. July 2005. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol 25(7):1401-1407.
22. Baynes JW, Thorpe SR. 2000. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28(12):1708-1716.
23. Beale SI. 1994. Biosynthesis of open-chain tetrapyrroles in plants, algae, and cyanobacteria. Ciba Found Symp 180:156-168.
24. Beckman JA, GoldfineAB, GordonMB, Garrett LA,Keaney JF, Jr., Creager MA. 2003.
25. Beckman JA, GoldfineAB, GordonMB, Garrett LA,Keaney JF, Jr., Creager MA. 2003.
26. Beltramo E, Berrone E, Buttiglieri S, Porta M. 2004. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev 20(4):330-336.
27. Berrone E, Beltramo E, Solimine C, Ubertalli AA, Porta M. 2006. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 281(4):9307-9313.
28. Bitsch R, Wolf M, Moller J, Heuzeroth L, Gruneklee D. 1991. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivative. Ann Nutr Metab 35(5):292-296.
29. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K. 2006. Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction. N Engl J Med 354(15):1578-1588.
30. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP. 1995. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333(18):1171-1175.
31. Brusq JM, Ancellin N, Grondin P, Guillard R, Martin S, Saintillan Y, Issandou M. 2006. Inhibition of lipid synthesis through activation of AMP kinase: An additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47(6):1281-1288.
32. Burnier M, Zanchi A. January 2006. Blockade of the renin-angiotensin-aldosterone system: A key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 24(1):11-25.
33. Bursell SE, Clermont AC, Aiello LP, Aiello LM, Schlossman DK, Feener EP, Laffel L, King GL. 1999. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 22(8):1245-1251.
34. Buse MG. 2006. Hexosamines, insulin resistance, and the complications of diabetes: Current status. Am J Physiol Endocrinol Metab 290(1):E1-E8.
35. Cabrera-Rode E, Molina G, Arranz C, Vera M, Gonzalez P, Suarez R, Prieto M, Padron S, Leon R, Tillan J, Garcia I, Tiberti C, Rodriguez OM, Gutierrez A, Fernandez T, Govea A, Hernandez J, Chiong D, Dominguez E, Di Mario U, Diaz-Diaz O, Diaz-Horta O. 2006. Effect of standard nicotinamide in the prevention of type 1 diabetes in first degree relatives of persons with type 1 diabetes. Autoimmunity 39(4):333-340.
36. Cacicedo JM, Benjachareowong S, Chou E, Ruderman NB, Ido Y. 2005. Palmitateinduced apoptosis in cultured bovine retinal pericytes: Roles of NAD(P)H oxidase, oxidant stress, and ceramide. Diabetes 54(6):1838-1845.
37. Cacicedo JM, Yagihashi N, Keaney JF, Jr, Ruderman NB, Ido Y. 2004. AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun 324(4):1204-1209.
38. Cai S, Khoo J, Mussa S, Alp NJ, Channon KM. 2005. Endothelial nitric oxide synthase dysfunction in diabetic mice: Importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia 48(9):1933-1940.
39. Cameron NE, Gibson TM, Nangle MR, Cotter MA. 2005. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann N Y Acad Sci 1043:784-792.
40. Carvajal SG, Juarez E, Ramos MG, Carvajal Juarez ME, Medina-Santillan R. 1999a. Inhibition of hemoglobin glycation with glycine in induced diabetes mellitus in rats. Proc West Pharmacol Soc 42:35-36.
41. Carvajal SG, Medina SR, Juarez E, RamosMartinez G, Carvajal Juarez ME. 1999b. Effect of glycine on hemoglobin glycation in diabetic patients. ProcWest Pharmacol Soc 42:31-32.
42. Cavallo A, Daniels SR, Dolan LM, Bean JA, Khoury JC. 2004a. Blood pressurelowering effect of melatonin in type 1 diabetes. J Pineal Res 36(4):262-266.
43. Cavallo A, Daniels SR, Dolan LM, Khoury JC, Bean JA. 2004b. Blood pressure response to melatonin in type 1 diabetes. Pediatr Diabetes 5(1):26-31.
44. Cha M, Park JR. 2005. Production and characterization of a soy protein-derived angiotensin I-converting enzyme inhibitory hydrolysate. J Med Food 8(3):305-310.
45. Chakraborty SK. 1992. Plasma ascorbate status in newly diagnosed diabetics exhibiting retinopathy-a finding that alarms. Bangladesh Med Res Counc Bull 18(1):30-35.
46. Chamorro G, Perez-Albiter M, Serrano-Garcia N, Mares-Samano JJ, Rojas P. 2006. Spirulina maxima pretreatment partially protects against 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine neurotoxicity. Nutr Neurosci 9(5-6):207-212.
47. Chandra D, Jackson EB, Ramana KV, Kelley R, Srivastava SK, Bhatnagar A. 2002. Nitric oxide prevents aldose reductase activation and sorbitol accumulation during diabetes. Diabetes 51(10):3095-3101.
48. Chandra A, Srivastava S, Petrash JM, Bhatnagar A, Srivastava SK. 1997. Active site modification of aldose reductase by nitric oxide donors. Biochim Biophys Acta 1341(2):217-222.
49. Chen H, Karne RJ, Hall G, Campia U, Panza JA, Cannon RO, III, Wang Y, Katz A, Levine M, Quon MJ. 2006. High-dose oral vitamin C partially replenishes vitamin C levels in patients with Type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance. Am J Physiol Heart Circ Physiol 290(1):H137-H145.
50. Christ M, Bauersachs J, Liebetrau C, Heck M, Gunther A, Wehling M. 2002. Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: Attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. Diabetes 51(8):2648-2652.
51. Chu KY, Lau T, Carlsson PO, Leung PS. 2006. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55(2):367-374.
52. Cooke CL, Davidge ST. 2002. Peroxynitrite increases iNOS through NF-kappaB and decreases prostacyclin synthase in endothelial cells. Am J Physiol Cell Physiol 282(2):C395-C402.
53. Cooper ME. 2004. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 17(11 Pt 2):16S-20S.
54. Cosentino F, Eto M, De Paolis P, Van Der LB, Bachschmid M, Ullrich V, Kouroedov A, Delli GC, Joch H, Volpe M, Luscher TF. 2003. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: Role of protein kinase C and reactive oxygen species. Circulation 107(7):1017-1023.
55. Cotter MA, Cameron NE. 2003. Effect of theNAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats. Life Sci 73(14):1813-1824.
56. Crary EJ, McCarty MF. 1984. Potential clinical applications for high-dose nutritional antioxidants. Med Hypotheses 13(1):77-98.
57. d'Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. 2003. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res 92(1):88-95.
58. Darko D, Dornhorst A, Kelly FJ, Ritter JM, Chowienczyk PJ. 2002. Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in Type II diabetes. Clin Sci (Lond) 103(4):339-344.
59. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW. 2002. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61(3):939-950.
60. Deinum J, Chaturvedi N. 2002. The Renin-Angiotensin system and vascular disease in diabetes. Semin Vasc Med 2(2):149-156.
61. Derlacz RA, Sliwinska M, Piekutowska A, Winiarska K, Drozak J, Bryla J. 2007. Melatonin is more effective than taurine and 5-hydroxytryptophan against hyperglycemia-induced kidney-cortex tubules injury. J Pineal Res 42(2):203-209.
62. Di Leo MA, Ghirlanda G, Gentiloni SN, Giardina B, Franconi F, Santini SA. 2003. Potential therapeutic effect of antioxidants in experimental diabetic retina: A comparison between chronic taurine and vitamin E plus selenium supplementations. Free Radic Res 37(3):323-330.
63. Di Leo MA, Santini SA, Cercone S, Lepore D, Gentiloni SN, Caputo S, Greco AV, Giardina B, Franconi F, Ghirlanda G. 2002. Chronic taurine supplementation ameliorates oxidative stress and Na+ K+ ATPase impairment in the retina of diabetic rats. Amino Acids 23(4):401-406.
64. Di Leo MA, Santini SA, Silveri NG, Giardina B, Franconi F, Ghirlanda G. 2004. Long-termtaurine supplementation reduces mortality rate in streptozotocin-induced diabetic rats. Amino Acids 27(2):187-191.
65. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F,Wu J, Brownlee M. 2000. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 97(22):12222-12226.
66. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M. 2003. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112(7):1049-1057.
67. Du X, Stocklauser-Farber K, Rosen P. 1999. Generation of reactive oxygen intermediates, activation of NF-kappaB, and induction of apoptosis in human endothelial cells by glucose: Role of nitric oxide synthase? Free Radic Biol Med 27(7-8):752-763.
68. Economides PA, Khaodhiar L, Caselli A, Caballero AE, Keenan H, Bursell SE, King GL, JohnstoneMT, Horton ES,Veves A. 2005. The effect of vitaminEon endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients. Diabetes 54(1):204-211.
69. Ek A, Strom K, Cotgreave IA. October 26, 1995. The uptake of ascorbic acid into human umbilical vein endothelial cells and its effect on oxidant insult. Biochem Pharmacol 50(9):1339-1346.
70. Elliott RB, Pilcher CC, Stewart A, Fergusson D, McGregor MA. November 30, 1993. The use of nicotinamide in the prevention of type 1 diabetes. Ann N Y Acad Sci 696:333-341.
71. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, Teboul M, Massiera F, Sharma AM. June 2003. The adipose-tissue renin-angiotensin-aldosterone system: Role in the metabolic syndrome? Int J Biochem Cell Biol 35(6):807-825.
72. Exner M, Minar E, Wagner O, Schillinger M. October 15, 2004. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med 37(8):1097-1104.
73. Faure P, Ramon O, Favier A, Halimi S. July 2004. Selenium supplementation decreases nuclear factor-kappa B activity in peripheral blood mononuclear cells from type 2 diabetic patients. Eur J Clin Invest 34(7):475-481.
74. Fennessy FM, Moneley DS,Wang JH, Kelly CJ, Bouchier-Hayes DJ. January 28, 2003. Taurine and vitamin C modify monocyte and endothelial dysfunction in young smokers. Circulation 107(3):410-415.
75. FisherND, Hughes M, Gerhard-Herman M, Hollenberg NK. December 2003. Flavanolrich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. J Hypertens 21(12):2281-2286.
76. Flier J, Van Muiswinkel FL, Jongenelen CA, Drukarch B. June 2002. The neuroprotective antioxidant alpha-lipoic acid induces detoxication enzymes in cultured astroglial cells. Free Radic Res 36(6):695-699.
77. Fontayne A, Dang PM, Gougerot-Pocidalo MA, el Benna J. June 18, 2002. Phosphorylation of p47phox sites by PKC alpha, beta II, delta, and zeta: Effect on binding to p22phox and on NADPH oxidase activation. Biochemistry 41(24):7743-7750.
78. Franconi F, Bennardini F, Mattana A, Miceli M, Ciuti M, Mian M, Gironi A, Anichini R, Seghieri G. May 1995. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: Effects of taurine supplementation. Am J Clin Nutr JID - 0376027 61(5):1115-1119.
79. Franconi F, Loizzo A, Ghirlanda G, Seghieri G. January 2006. Taurine supplementation and diabetes mellitus. Curr Opin Clin Nutr Metab Care 9(1):32-36.
80. Franconi F, Miceli M, Bennardini F, Mattana A, Covarrubias J, Seghieri G. 1992.Taurine potentiates the antiaggregatory action of aspirin and indomethacin. Adv Exp Med Biol JID - 0121103 315:181-186.
81. Franconi F, Miceli M, Bennardini F, Mattana A, Covarrubias J, Seghieri G. 1992.Taurine potentiates the antiaggregatory action of aspirin and indomethacin. Adv Exp Med Biol JID - 0121103 315:181-186.
82. Fujita T, Ando K, Noda H, Ito Y, Sato Y. March 1987. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation 75(3):525-532.
83. Fujita M, Okuda H, TsukamotoO, AsanoY, Hirata YL, Kim J, Miyatsuka T, Takashima S, Minamino T, Tomoike H, Kitakaze M. October 2006. Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler Thromb Vasc Biol 26(10):e138-e142.
84. Fujita H, Yoshikawa M. October 15, 1999. LKPNM: A prodrug-type ACE-inhibitory peptide derived from fish protein. Immunopharmacology 44(1-2):123-127.
85. Fukino Y, Shimbo M, Aoki N, Okubo T, Iso H. October 2005. Randomized controlled trial for an effect of green tea consumption on insulin resistance and inflammation markers. J Nutr Sci Vitaminol (Tokyo) 51(5):335-342.
86. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. December 2004. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114(12):1752-1761.
87. Gadau S, Emanueli C, Van Linthout S, Graiani G, Todaro M, Meloni M, Campesi I, Invernici G, Spillmann F, Ward K, Madeddu P. February 2006. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 49(2):405-420.
88. Gale EA. May 1996. Theory and practice of nicotinamide trials in pre-type 1 diabetes. J Pediatr Endocrinol Metab 9(3):375-379.
89. Gale EA, Bingley PJ, Emmett CL, Collier T. March 20, 2004. European Nicotinamide Diabetes Intervention Trial (ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363(9413):925-931.
90. Gazis A, White DJ, Page SR, Cockcroft JR. April 1999. Effect of oral vitamin E (alphatocopherol) supplementation on vascular endothelial function in Type 2 diabetes mellitus. Diabet Med 16(4):304-311.
91. Gilbert RE, KrumH,Wilkinson-Berka J,Kelly DJ. August 2003. The renin-angiotensin system and the long-term complications of diabetes: Pathophysiological and therapeutic considerations. Diabet Med 20(8):607-621.
92. Gokce N, Keaney JF, Jr, Frei B, Holbrook M, Olesiak M, Zachariah BJ, Leeuwenburgh C, Heinecke JW, Vita JA. June 29, 1999. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 99(25):3234-3240.
93. GrassiD, Necozione S, Lippi C, Croce G,Valeri L, Pasqualetti P, Desideri G, Blumberg JB, Ferri C. August 2005. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension 46(2):398-405.
94. Green K, Brand MD, Murphy MP. February 2004. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 53(Suppl 1):S110-S118.
95. Ha E,YimSV, Chung JH,Yoon KS, Kang I, Cho YH, Baik HH. August 2006. Melatonin stimulates glucose transport via insulin receptor substrate-1/phosphatidylinositol 3- kinase pathway in C2C12 murine skeletal muscle cells. J Pineal Res 41(1):67-72.
96. Ha H,YuMR,KimKH. April 1999. Melatonin and taurine reduce early glomerulopathy in diabetic rats. Free Radic Biol Med 26(7-8):944-950.
97. Hahm JR, Kim BJ, Kim KW. March 2004. Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients. J Diabetes Complications 18(2):79-85.
98. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. March 2003. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9(3):294-299.
99. Harada H, Kitazaki K, Tsujino T,Watari Y, Iwata S, Nonaka H, Hayashi T, Takeshita T, Morimoto K, Yokoyama M. May 2000. Oral taurine supplementation prevents the development of ethanol-induced hypertension in rats. Hypertens Res JID - 9307690 23(3):277-284.
100. Hardeland R. July 2005. Antioxidative protection by melatonin: Multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 27(2):119-130.
101. Hartikainen H. 2005. Biogeochemistry of selenium and its impact on food chain quality and human health. J Trace Elem Med Biol 18(4):309-318.
102. Hassa PO, Haenni SS, Buerki C, Meier NI, Lane WS, Owen H, Gersbach M, Imhof R, Hottiger MO. December 9, 2005. Acetylation of poly(ADP-ribose) polymerase- 1 by p300/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription. J Biol Chem 280(49):40450-40464.
103. Haupt E, Ledermann H, Kopcke W. February 2005. Benfotiamine in the treatment of diabetic polyneuropathy-a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 43(2):71-77.
104. Hayes KC, Pronczuk A, Addesa AE, Stephan ZF. June 1989. Taurine modulates platelet aggregation in cats and humans. Am J Clin Nutr JID - 0376027 49(6):1211-1216.
105. Heidland A, Sebekova K, Schinzel R. October 2001. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 38(4 Suppl 1):S100-S106.
106. Heitzer T, Krohn K, Albers S, Meinertz T. November 2000. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 43(11):1435-1438.
107. Heller R, Munscher-Paulig F, Grabner R, Till U. March 19, 1999. L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J Biol Chem 274(12):8254-8260.
108. Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-felmayer G, Werner ER. January 5, 2001. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 276(1):40-47.
109. Hollenberg NK, Martinez G, McCullough M, Meinking T, PassanD, Preston M, Rivera A, Taplin D, Vicaria-Clement M. January 1997. Aging, acculturation, salt intake, and hypertension in the Kuna of Panama. Hypertension 29(1 Pt 2):171-176.
110. Holzmeister J, Graf K,Warnecke C, Fleck E, Regitz-Zagrosek V. August 1997. Protein kinase C-dependent regulation of the human AT1 promoter in vascular smooth muscle cells. Am J Physiol 273(2 Pt 2):H655-H664.
111. Hori O, Yan SD, Ogawa S, Kuwabara K, Matsumoto M, Stern D, Schmidt AM. 1996. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrol Dial Transplant 11(Suppl 5):13-16.
112. Huang A, Vita JA, Venema RC, Keaney JF, Jr. June 9, 2000. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem 275(23):17399-17406.
113. Hughes DB, Britton ML. November 2005. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus. Pharmacotherapy 25(11):1602-1620.
114. Hussain SA, Khadim HM, Khalaf BH, Ismail SH, Hussein KI, Sahib AS. October 2006. Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin. Saudi Med J 27(10):1483-1488.
115. Hyndman ME, Verma S, Rosenfeld RJ, Anderson TJ, Parsons HG. June 2002. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol 282(6):H2167-H2172.
116. Ideishi M, Miura S, Sakai T, Sasaguri M, Misumi Y, Arakawa K. June 1994. Taurine amplifies renal kallikrein and prevents salt-induced hypertension in Dahl rats. J Hypertens JID - 8306882 12(6):653-661.
117. Ikejima K, Qu W, Stachlewitz RF, Thurman RG. June 1997. Kupffer cells contain a glycine-gated chloride channel. Am J Physiol 272(6 Pt 1):G1581-G1586
118. InoguchiT, Li P, Umeda F,YuHY, Kakimoto M, Imamura M, AokiT, EtohT, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H. November 2000. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49(11):1939-1945.
119. Inoguchi T, Nawata H. June 2005. NAD(P)H oxidase activation: A potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Curr Drug Targets 6(4):495-501.
120. Inoguchi T, Sasaki S, Kobayashi K, Takayanagi R, Yamada T. September 26, 2007. Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA 298(12):1398-1400.
121. Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N, Sato N, Sekiguchi N,Kobayashi K, Sumimoto H, Utsumi H, Nawata H. August 2003. Protein kinase Cdependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: Role of vascular NAD(P)H oxidase. J Am Soc Nephrol 14(8 Suppl 3):S227-S232.
122. Ishii H, Koya D, King GL. January 1998. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 76(1):21-31.
123. Iso H, Date C, Wakai K, Fukui M, Tamakoshi A. April 18, 2006. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Ann Intern Med 144(8):554-562.
124. Jaimes EA, Sweeney C, Raij L. October 2001. Effects of the reactive oxygen species hydrogen peroxide and hypochlorite on endothelial nitric oxide production. Hypertension 38(4):877-883.
125. Jain AK, Lim G, Langford M, Jain SK. December 15, 2002. Effect of high-glucose levels on protein oxidation in cultured lens cells, and in crystalline and albumin solution and its inhibition by vitamin B6 and N-acetylcysteine: Its possible relevance to cataract formation in diabetes. Free Radic Biol Med 33(12):1615-1621.
126. Jiang C, Ganther H, Lu J. December 2000. Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: Implications for angiogenic switch regulation. Mol Carcinog 29(4):236-250.
127. Jiang C, Jiang W, Ip C, Ganther H, Lu J. December 1999. Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog 26(4):213-225.
128. JonasWB, Rapoza CP, BlairWF. July 1996. The effect of niacinamide on osteoarthritis: A pilot study. Inflamm Res 45(7):330-334.
129. Kadhim HM, Ismail SH, Hussein KI, Bakir IH, Sahib AS, Khalaf BH, Hussain SA. September 2006. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin. J Pineal Res 41(2):189-193.
130. Kalousova M, Novotny L, Zima T, Braun M, Vitek L. September 30, 2005. Decreased levels of advanced glycation end-products in patients with Gilbert syndrome. Cell Mol Biol 51(4):387-392.
131. Kanayama A, Inoue J, Sugita-KonishiY, Shimizu M, MiyamotoY. July 5, 2002. Oxidation of Ikappa Balpha at methionine 45 is one cause of taurine chloramine-induced inhibition of NF-kappa B activation. J Biol Chem 277(27):24049-24056.
132. Karachalias N, Babaei-Jadidi R, Kupich C, Ahmed N, Thornalley PJ. June 2005. Highdose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats. Ann N Y Acad Sci 1043:777-783.
133. Khan SG, Katiyar SK, Agarwal R, Mukhtar H. July 15, 1992. Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: Possible role in cancer chemoprevention. Cancer Res 52(14):4050-4052.
134. Khan M, Shobha JC, Mohan IK, Naidu MU, Sundaram C, Singh S, Kuppusamy P, Kutala VK. December 2005. Protective effect of Spirulina against doxorubicininduced cardiotoxicity. Phytother Res 19(12):1030-1037.
135. Khan M, Shobha JC, Mohan IK, Rao Naidu MU, Prayag A, Kutala VK. September 2006. Spirulina attenuates cyclosporine-induced nephrotoxicity in rats. J Appl Toxicol 26(5):444-451.
136. Kim MS, Park JY, Namkoong C, Jang PG, Ryu JW, Song HS, Yun JY, Namgoong IS, Ha J, Park IS, Lee IK, Viollet B, Youn JH, Lee HK, Lee KU. July 2004. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med 10(7):727-733.
137. Kim F, Tysseling KA, Rice J, Pham M, Haji L, Gallis BM, Baas AS, Paramsothy P, Giachelli CM, Corson MA, Raines EW. May 2005. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol 25(5):989-994.
138. Knekt P, Ritz J, Pereira MA, O'Reilly EJ, Augustsson K, Fraser GE, Goldbourt U, Heitmann BL, Hallmans G, Liu S, Pietinen P, SpiegelmanD, Stevens J,Virtamo J,Willett WC, Rimm EB, Ascherio A. December 2004. Antioxidant vitamins and coronary heart disease risk: A pooled analysis of 9 cohorts. Am J Clin Nutr 80(6):1508-1520.
139. Knip M, Douek IF, MooreWP, Gillmor HA, McLean AE, Bingley PJ, Gale EA. November 2000. Safety of high-dose nicotinamide: A review. Diabetologia 43(11):1337-1345.
140. Ko SH, Hong OK, Kim JW, Ahn YB, Song KH, Cha BY, Son HY, Kim MJ, Jeong IK, Yoon KH. January 11, 2006. High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system. J Cell Biochem 98(2):343-355.
141. Kohashi N, Okabayashi T, Hama J, Katori R. 1983. Decreased urinary taurine in essential hypertension. Prog Clin Biol Res 125:73-87.
142. Kondo Y, Murakami S, Oda H, Nagate T. 2000. Taurine reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Adv Exp Med Biol JID - 0121103 483:193-202.
143. Kowluru RA, Odenbach S. December 2004. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 53(12):3233-3238.
144. KoyaD, Haneda M, Kikkawa R, King GL. 1998. d-alpha-tocopherol treatment prevents glomerular dysfunctions in diabetic rats through inhibition of protein kinase Cdiacylglycerol pathway. Biofactors 7(1-2):69-76.
145. Koya D, Lee IK, Ishii H, Kanoh H, King GL. March 1997. Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. JAmSoc Nephrol 8(3):426-435.
146. Koyama Y, Abe K, Sano Y, Ishizaki Y, Njelekela M, Shoji Y, Hara Y, Isemura M. November 2004. Effects of green tea on gene expression of hepatic gluconeogenic enzymes in vivo. Planta Med 70(11):1100-1102.
147. Krebs M, Roden M. November 2005. Molecular mechanisms of lipid-induced insulin resistance in muscle, liver and vasculature. Diabetes Obes Metab 7(6):621-632.
148. KubaM,Tanaka K,Tawata S,TakedaY,YasudaM.June 2003. Angiotensin I-converting enzyme inhibitory peptides isolated from tofuyo fermented soybean food. Biosci Biotechnol Biochem 67(6):1278-1283.
149. Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, Yano M, Motoshima H, Taguchi T, Matsumura T, Araki E. January 2006. Activation of AMPactivated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 55(1):120-127.
150. Kunisaki M, Bursell SE, Clermont AC, Ishii H, Ballas LM, Jirousek MR, Umeda F, Nawata H, King GL. August 1995. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol 269(2 Pt 1):E239-E246.
151. Kunisaki M, Bursell SE, Umeda F, Nawata H, King GL.November 1994. Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes 43(11):1372-1377.
152. Kunisaki M, Bursell SE, Umeda F, Nawata H, King GL. 1998. Prevention of diabetesinduced abnormal retinal blood flow by treatment with d-alpha-tocopherol. Biofactors 7(1-2):55-67.
153. Kunisaki M, Fumio U, Nawata H, King GL. July 1996. Vitamin E normalizes diacylglycerol-protein kinase C activation induced by hyperglycemia in rat vascular tissues. Diabetes 45(Suppl 3):S117-S119.
154. Lampeter EF, Klinghammer A, ScherbaumWA, Heinze E, HaastertB, Giani G,Kolb H. June 1998. The Deutsche Nicotinamide Intervention Study: An attempt to prevent type 1 diabetes. DENIS Group. Diabetes 47(6):980-984.
155. Lanone S, Bloc S, Foresti R, Almolki A, Taille C, Callebert J, Conti M, GovenD, Aubier M, Dureuil B, el Benna J, Motterlini R, Boczkowski J. November 2005. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: Implications for protection against endotoxic shock in rats. FASEB J 19(13):1890-1892.
156. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C, Gosby A, Kraegen EW, James DE, Kim JB. August 2006. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55(8):2256-2264.
157. Lee WJ, Lee IK, Kim HS, Kim YM, Koh EH, Won JC, Han SM, Kim MS, Jo I, Oh GT, Park IS, Youn JH, Park SW, Lee KU, Park JY. December 2005a. Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase. Arterioscler Thromb Vasc Biol 25(12):2488-2494.
158. Lee WJ, Song KH, Koh EH, Won JC, Kim HS, Park HS, Kim MS, Kim SW, Lee KU, Park JY. July 8, 2005b. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun 332(3):885-891.
159. Li F, Abatan OI, Kim H, Burnett D, Larkin D, Obrosova IG, Stevens MJ. April 17, 2006. Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats. Neurobiol Dis 22(3):669-676.
160. Li F, Drel VR, Szabo C, Stevens MJ, Obrosova IG. May 2005. Low-dose poly(ADPribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy. Diabetes 54(5):1514-1522.
161. Li F, Obrosova IG, Abatan O, Tian D, Larkin D, Stuenkel EL, Stevens MJ. January 2005. Taurine replacement attenuates hyperalgesia and abnormal calcium signaling in sensory neurons of STZ-D rats.AmJ Physiol Endocrinol Metab 288(1):E29-E36.
162. Li J, Schmidt AM. June 27, 1997. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 272(26):16498-16506.
163. Lo WM, Li-Chan EC. May 4, 2005. Angiotensin I converting enzyme inhibitory peptides from in vitro pepsin-pancreatin digestion of soy protein. J Agric Food Chem 53(9):3369-3376.
164. Loew D. February 1996. Pharmacokinetics of thiamine derivatives especially of benfotiamine. Int J Clin Pharmacol Ther 34(2):47-50.
165. Lonn E,Yusuf S, Hoogwerf B, Pogue J,Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, Gerstein HC. November 2002. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: Results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25(11):1919-1927.
166. Mangoni AA, Sherwood RA, AsonganyiB, Swift CG, Thomas S, Jackson SH. February 2005. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am J Hypertens 18(2 Pt 1):220-226.
167. Manna R, Migliore A, Martin LS, Ferrara E, Ponte E, Marietti G, Scuderi F, Cristiano G, Ghirlanda G, Gambassi G. 1992. Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion. Br J Clin Pract 46(3):177-179.
168. Marczak ED, Usui H, Fujita H, Yang Y, Yokoo M, Lipkowski AW, Yoshikawa M. June 2003. New antihypertensive peptides isolated from rapeseed. Peptides 24(6):791-798.
169. Mayer M. November 2000. Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem 46(11):1723-1727.
170. Mayo JC, Sainz RM, Antoli I, Herrera F, Martin V, Rodriguez C. October 2002. Melatonin regulation of antioxidant enzyme gene expression. Cell Mol Life Sci 59(10):1706-1713.
171. McCarty MF. October 1999. The reported clinical utility of taurine in ischemic disorders may reflect a down-regulation of neutrophil activation and adhesion. Med Hypotheses 53(4):290-299.
172. McCarty MF. 2004a. Coping with endothelial superoxide: Potential complementarity of arginine and high-dose folate. Med Hypotheses 63(4):709-718.
173. McCarty MF. 2004b. Supplementary taurine may stabilize atheromatous plaque by antagonizing the activation of metalloproteinases by hypochlorous acid. Med Hypotheses 63(3):414-418.
174. McCarty MF. 2005a. AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome. Med Hypotheses 64(6):1211-1215.
175. McCarty MF. 2005b. The putative therapeutic value of high-dose selenium in proliferative retinopathies may reflect down-regulation of VEGF production by the hypoxic retina. Med Hypotheses 64(1):159-161.
176. McCarty MF. 2006. Adjuvant strategies for prevention of glomerulosclerosis. Med Hypotheses 67(6):1277-1296.
177. McCarty MF. 2007a. "Iatrogenic Gilbert syndrome"-a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 69(5):974-994.
178. McCarty MF. 2007b. Oster rediscovered-mega-dose folate for treatment of symptomatic atherosclerosis. Med Hypotheses 69(2):325-332.
179. McCarty MF. 2007c. High-dose folate may have clinical potential as a scavenger of peroxynitrite-derived radicals. Med Hypotheses, submitted for publication. McCarty MF. 2007d. The hyperpolarizing impact of glycine on endothelial cells may be anti-atherogenic. Med Hypotheses, in press.
180. McCarty MF, Russell AL. October 1999. Niacinamide therapy for osteoarthritis- does it inhibit nitric oxide synthase induction by interleukin 1 in chondrocytes? Med Hypotheses 53(4):350-360.
181. McFarlane SI, Kumar A, Sowers JR. June 2003. Mechanisms by which angiotensinconverting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 91(12A):30H-37H.
182. Metz TO, Alderson NL, Thorpe SR, Baynes JW. November 1, 2003. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: A novel therapy for treatment of diabetic complications. Arch Biochem Biophys 419(1):41-49.
183. Milstien S, Katusic Z. October 5, 1999. Oxidation of tetrahydrobiopterin by peroxynitrite: Implications for vascular endothelial function. Biochem Biophys ResCommun 263(3):681-684.
184. Mizuno S, Matsuura K, Gotou T, Nishimura S, Kajimoto O, Yabune M, Kajimoto Y, Yamamoto N. July 2005. Antihypertensive effect of casein hydrolysate in a placebocontrolled study in subjects with high-normal blood pressure and mild hypertension. Br J Nutr 94(1):84-91.
185. Moat SJ, Clarke ZL, Madhavan AK, Lewis MJ, Lang D. January 20, 2006. Folic acid reverses endothelial dysfunction induced by inhibition of tetrahydrobiopterin biosynthesis. Eur J Pharmacol 530(3):250-258.
186. Mohan IK, Khan M, Shobha JC, Naidu MU, Prayag A, Kuppusamy P, Kutala VK. December 2006. Protection against cisplatin-induced nephrotoxicity by Spirulina in rats. Cancer Chemother Pharmacol 58(6):802-808.
187. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Forstermann U, Meinertz T, Griendling K, Munzel T. March 8, 2002. Effects of angiotensin II infusion on the expression and function ofNAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90(4):E58-E65.
188. Montilla PL, Vargas JF, Tunez IF, Munoz de Agueda MC, Valdelvira ME, Cabrera ES. September 1998. Oxidative stress in diabetic rats induced by streptozotocin: Protective effects of melatonin. J Pineal Res 25(2):94-100.
189. Morcos M, Borcea V, Isermann B, Gehrke S, Ehret T, Henkels M, Schiekofer S, Hofmann M, Amiral J, Tritschler H, Ziegler R, Wahl P, Nawroth PP. June 2001. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: An exploratory study. Diabetes Res Clin Pract 52(3):175-183.
190. Morita T. September 2005. Heme oxygenase and atherosclerosis. Arterioscler Thromb Vasc Biol 25(9):1786-1795.
191. Murakami S, Kondo Y, Sakurai T, Kitajima H, Nagate T. July 2002. Taurine suppresses development of atherosclerosis inWatanabe heritable hyperlipidemic (WHHL) rabbits. Atherosclerosis JID - 0242543 163(1):79-87.
192. Murakami M, Tonouchi H, Takahashi R, Kitazawa H, Kawai Y, Negishi H, Saito T. July 2004. Structural analysis of a new anti-hypertensive peptide (beta-lactosin B) isolated from a commercial whey product. J Dairy Sci 87(7):1967-1974.
193. Nakajima H, Nagaso H, Kakui N, Ishikawa M, Hiranuma T, Hoshiko S. October 8, 2004. Critical role of the automodification of poly(ADP-ribose) polymerase-1 in nuclear factor-kappaB-dependent gene expression in primary cultured mouse glial cells. J Biol Chem 279(41):42774-42786.
194. Nakamura T, Ushiyama C, Suzuki S, Shimada N, Ohmuro H, Ebihara I, Koide H. 1999. Effects of taurine and vitamin E on microalbuminuria, plasma metalloproteinase-9, and serum type IV collagen concentrations in patients with diabetic nephropathy. Nephron 83(4):361-362.
195. Nakayama M, Inoguchi T, Sonta T, MaedaY, Sasaki S, Sawada F, Tsubouchi H, Sonoda N, Kobayashi K, Sumimoto H, Nawata H. July 15, 2005. Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochem Biophys Res Commun 332(4):927-933.
196. Nara Y, Yamori Y, Lovenberg W. 1978. Effect of dietary taurine on blood pressure in spontaneously hypertensive rats. Biochem Pharmacol JID - 0101032 27(23):2689-2692.
197. Negrisanu G, Rosu M, Bolte B, Lefter D, Dabelea D. July 1999. Effects of 3-month treatment with the antioxidant alpha-lipoic acid in diabetic peripheral neuropathy. Rom J Intern Med 37(3):297-306.
198. Ni YX. December 1988. Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research. Zhong Xi Yi Jie He Za Zhi 8(12):711-713, 707.
199. Nishida S. July 2005. Metabolic effects of melatonin on oxidative stress and diabetes mellitus. Endocrine 27(2):131-136.
200. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, BeebeD, Oates PJ, Hammes HP, Giardino I, Brownlee M. April 13, 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404(6779):787-790.
201. Nordberg J, Arner ES. December 1, 2001. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 31(11):1287-1312.
202. Obrosova IG, Fathallah L, Stevens MJ. November 2001a. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp Neurol 172(1):211-219.
203. Obrosova IG, Li F, Abatan OI, Forsell MA, Komjati K, Pacher P, Szabo C, Stevens MJ. March 2004a. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53(3):711-720.
204. Obrosova IG, Mabley JG, Zsengeller Z, Charniauskaya T, Abatan OI, Groves JT, Szabo C. March 2005. Role for nitrosative stress in diabetic neuropathy: Evidence from studies with a peroxynitrite decomposition catalyst. FASEB J 19(3):401-403.
205. Obrosova IG, Minchenko AG, Frank RN, Seigel GM, Zsengeller Z, Pacher P, Stevens MJ, Szabo C. July 2004b. Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. Int J Mol Med 14(1):55-64.
206. Obrosova IG, Minchenko AG, Marinescu V, Fathallah L, Kennedy A, Stockert CM, Frank RN, Stevens MJ. September 2001b. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 44(9):1102-1110.
207. Ogborne RM, Rushworth SA, O'Connell MA. October 2005. Alpha-lipoic acidinduced heme oxygenase-1 expression is mediated by nuclear factor erythroid 2- related factor 2 and p38 mitogen-activated protein kinase in human monocytic cells. Arterioscler Thromb Vasc Biol 25(10):2100-2105.
208. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z. December 2002. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 16(14):1928-1930.
209. Okumura M, Masada M, Yoshida Y, Shintaku H, Hosoi M, Okada N, Konishi Y, Morikawa T, Miura K, Imanishi M. August 2006. Decrease in tetrahydrobiopterin as a possible cause of nephropathy in type II diabetic rats. Kidney Int 70(3):471-476.
210. Olmos PR, Hodgson MI, Maiz A, Manrique M, De ValdesMD, Foncea R, Acosta AM, Emmerich MV, Velasco S, Muniz OP, Oyarzun CA, Claro JC, Bastias MJ, Toro LA. March 2006. Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics. Diabetes Res Clin Pract 71(3):320-333.
211. Oster KA. October 1968. Treatment of angina pectoris according to a new theory of its origin. Cardiol Dig 3:29-34. Oster KA, Ross DJ, Dawkins HHR. 1983. The XO Factor. New York: Park City Press.
212. Ouslimani N, Peynet J, Bonnefont-Rousselot D, Therond P, Legrand A, Beaudeux JL. June 2005. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 54(6):829-834.
213. Pacher P, Szabo C. November 2005. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: Endothelial dysfunction, as acommon underlying theme. Antioxid Redox Signal 7(11-12):1568-1580.
214. Pacher P, Szabo C. April 2006. Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol 6(2):136-141.
215. Padival S, Nagaraj RH. 2006. Pyridoxamine inhibits maillard reactions in diabetic rat lenses. Ophthalmic Res 38(5):294-302.
216. Pannirselvam M, Simon V, Verma S, Anderson T, Triggle CR. October 2003. Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice. Br J Pharmacol 140(4):701-706.
217. Paskaloglu K, Sener G, Ayangolu-Dulger G. September 24, 2004. Melatonin treatment protects against diabetes-induced functional and biochemical changes in rat aorta and corpus cavernosum. Eur J Pharmacol 499(3):345-354.
218. Pekovich SR, Martin PR, Singleton CK. April 1998. Thiamine deficiency decreases steady-state transketolase and pyruvate dehydrogenase but not alpha-ketoglutarate dehydrogenase mRNA levels in three human cell types. J Nutr 128(4):683-687.
219. Pena AS, Wiltshire E, Gent R, Hirte C, Couper J. April 2004. Folic acid improves endothelial function in children and adolescents with type 1 diabetes. J Pediatr 144(4):500-504.
220. Petty MA, Kintz J, DiFrancesco GF. May 3, 1990. The effects of taurine on atherosclerosis development in cholesterol-fed rabbits. Eur J Pharmacol 180(1):119-127.
221. Piconi L, Quagliaro L, Da Ros R, Assaloni R, Giugliano D, Esposito K, Szabo C, Ceriello A. August 2004. Intermittent high glucose enhances ICAM-1, VCAM- 1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: The role of poly(ADP-ribose) polymerase. J Thromb Haemost 2(8):1453-1459.
222. Pieper GM. January 1997. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol 29(1):8-15.
223. Pociot F, Reimers JI, Andersen HU. June 1993. Nicotinamide-biological actions and therapeutic potential in diabetes prevention. IDIG Workshop, Copenhagen, Denmark, December 4-5, 1992. Diabetologia 36(6):574-576.
224. Pomero F, Molinar MA, La Selva M, Allione A, Molinatti GM, Porta M. 2001. Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose. Acta Diabetol 38(3):135-138.
225. Pop-Busui R, Sullivan KA, Van Huysen C, Bayer L, Cao X, Towns R, Stevens MJ. April 2001. Depletion of taurine in experimental diabetic neuropathy: Implications for nerve metabolic, vascular, and functional deficits. Exp Neurol 168(2):259-272.
226. Prabhakar SS. July 2001. Tetrahydrobiopterin reverses the inhibition of nitric oxide by high glucose in cultured murine mesangial cells. Am J Physiol Renal Physiol 281(1):F179-F188.
227. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. March 2000. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 20(3):645-651.
228. Ramana KV, Chandra D, Srivastava S, Bhatnagar A, Srivastava SK. March 2003. Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells. FASEB J 17(3):417-425.
229. Rask-Madsen C, King GL. March 2005. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 25(3):487-496.
230. Rasool M, Sabina EP, Lavanya B. December 2006. Anti-inflammatory effect of Spirulina fusiformis on adjuvant-induced arthritis in mice. Biol Pharm Bull 29(12):2483-2487.
231. Reiter RJ, Tan DX, Cabrera J, D'Arpa D, Sainz RM, Mayo JC, Ramos S. January 1999. The oxidant/antioxidant network: Role of melatonin. Biol Signals Recept 8(1-2):56-63.
232. Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Moller W, Tritschler HJ, Mehnert H. September 1999. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): A two year multicenter randomized doubleblind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 31(3):171-179.
233. Remirez D, Gonzalez R, Merino N, Rodriguez S, Ancheta O. April 2002. Inhibitory effects of Spirulina in zymosan-induced arthritis in mice. Mediators Inflamm 11(2):75-79.
234. Reyes-Toso CF, Linares LM, Ricci CR, Aran M, Pinto JE, Rodriguez RR, Cardinali DP. May 7, 2004. Effect of melatonin on vascular reactivity in pancreatectomized rats. Life Sci 74(25):3085-3092.
235. Rezk BM, Haenen GR, Van dV, Bast A. December 18, 2003. Tetrahydrofolate and 5-methyltetrahydrofolate are folates with high antioxidant activity. Identification of the antioxidant pharmacophore. FEBS Lett 555(3):601-605.
236. Rigato I, Ostrow JD, Tiribelli C. June 2005. Bilirubin and the risk of common nonhepatic diseases. Trends Mol Med 11(6):277-283.
237. Rindi G, LaforenzaU. September 2000. Thiamine intestinal transport and related issues: Recent aspects. Proc Soc Exp Biol Med 224(4):246-255.
238. Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V, Reiter RJ. January 2004. Regulation of antioxidant enzymes: A significant role for melatonin. J Pineal Res 36(1):1-9.
239. Romay C, Gonzalez R, Ledon N, Remirez D, Rimbau V. June 2003. C-phycocyanin: A biliprotein with antioxidant, anti-inflammatory and neuroprotective effects. Curr Protein Pept Sci 4(3):207-216.
240. Ruderman NB, Cacicedo JM, Itani S, Yagihashi N, Saha AK, Ye JM, Chen K, Zou M, Carling D, Boden G, Cohen RA, Keaney J, Kraegen EW, Ido Y. February 2003. Malonyl-CoA and AMP-activated protein kinase (AMPK): Possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem Soc Trans 31(Pt 1):202-206.
241. Ryu OH, Lee J, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. March 2006. Effects of green tea consumption on inflammation, insulin resistance and pulse wave velocity in type 2 diabetes patients. Diabetes Res Clin Pract 71(3):356-358.
242. Sato Y, Ogata E, Fujita T. May 1991. Hypotensive action of taurine in DOCA-salt rats-involvement of sympathoadrenal inhibition and endogenous opiate. Jpn Circ J JID-7806868 55(5):500-508.
243. Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, Sasaki T, Tsujioka K, Makino H, Kashihara N. June 2005. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 288(6):F1144-F1152.
244. Schreeb KH, Freudenthaler S, Vormfelde SV, Gundert-Remy U, Gleiter CH. 1997. Comparative bioavailability of two vitamin B1 preparations: Benfotiamine and thiamine mononitrate. Eur J Clin Pharmacol 52(4):319-320.
245. Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, Sies H, Kwik-Uribe C, Schmitz HH, Kelm M. January 24, 2006. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci U S A 103(4):1024-1029.
246. Schuller-Levis GB, Park E. September 26, 2003. Taurine: New implications for an old amino acid. FEMS Microbiol Lett 226(2):195-202.
247. SedlakTW, Snyder SH. June 2004. Bilirubin benefits: Cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics 113(6):1776-1782.
248. Seppo L, Jauhiainen T, Poussa T, Korpela R. February 2003. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 77(2):326-330.
249. Seshiah PN,Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. September 6, 2002. Angiotensin II stimulation ofNAD(P)Hoxidase activity: Upstream mediators. Circ Res 91(5):406-413.
250. Shankar SS, Steinberg HO. February 2005. FFAs: Do they play a role in vascular disease in the insulin resistance syndrome? Curr Diab Rep 5(1):30-35.
251. Shao J, Iwashita N, Ikeda F, Ogihara T, Uchida T, Shimizu T, Uchino H, Hirose T, Kawamori R, Watada H. June 16, 2006. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice. Biochem Biophys Res Commun 344(4):1224-1233.
252. Sherman DL, Keaney JF, Jr, Biegelsen ES, Duffy SJ, Coffman JD, Vita JA. April 2000. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension 35(4):936-941.
253. Shinozaki K, Kashiwagi A, Masada M, Okamura T. March 2004. Molecular mechanisms of impaired endothelial function associated with insulin resistance. Curr Drug Targets Cardiovasc Haematol Disord 4(1):1-11.
254. Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, Masada M, Toda N, Kikkawa R. December 1999. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2- imbalance in insulin-resistant rat aorta. Diabetes 48(12):2437-2445.
255. Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, Kojima H, Masada M, Toda N, Kikkawa R, Kashiwagi A. September 29, 2000. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res 87(7):566-573.
256. Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, Kojima H, Masada M, Toda N, Kikkawa R, Kashiwagi A. September 29, 2000. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res 87(7):566-573.
257. Shinozaki K, Nishio Y, Yoshida Y, Koya D, Ayajiki K, Masada M, Kashiwagi A, Okamura T. October 2005. Supplement of tetrahydrobiopterin by a gene transfer of GTP cyclohydrolase I cDNA improves vascular dysfunction in insulin-resistant rats. J Cardiovasc Pharmacol 46(4):505-512.
258. Sies H, Klotz LO, Sharov VS, Assmann A, Briviba K. March 1998. Protection against peroxynitrite by selenoproteins. Z Naturforsch [C] 53(3-4):228-232.
259. Sinclair AJ, Girling AJ, Gray L, Le Guen C, Lunec J, Barnett AH. March 1991. Disturbed handling of ascorbic acid in diabetic patients with and without microangiopathy during high dose ascorbate supplementation. Diabetologia 34(3):171-175.
260. Siu B, Saha J, Smoyer WE, Sullivan KA, Brosius FC, III. March 15, 2006. Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: Prevention by lipoic acid treatment. BMC Nephrol 7:6.
261. Skyrme-Jones RA, O'Brien RC, Berry KL, Meredith IT. July 2000. Vitamin E supplementation improves endothelial function in type I diabetes mellitus: A randomized, placebo-controlled study. J Am Coll Cardiol 36(1):94-102.
262. Sodhi CP, Kanwar YS, Sahai A. March 2003. Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells. Am J Physiol Heart Circ Physiol 284(3):H846-H852.
263. Sohn HY, Krotz F, Zahler S, Gloe T, Keller M, Theisen K, Schiele TM, Klauss V, Pohl U. March 2003. Crucial role of local peroxynitrite formation in neutrophil-induced endothelial cell activation. Cardiovasc Res 57(3):804-815.
264. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. October 12, 2001. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADPribose) polymerase. Circ Res 89(8):684-691.
265. Southan GJ, Szabo C. February 2003. Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 10(4):321-340.
266. Stadtman TC. 2000. Selenium biochemistry. Mammalian selenoenzymes. Ann N Y Acad Sci 899:399-402.
267. Stevens MJ, Li F, Drel VR, Abatan OI, Kim H, Burnett D, Larkin D, Obrosova IG. January 2007. Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats. J Pharmacol Exp Ther 320(1):458-464.
268. Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR. September 2002. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51(9):2826-2832.
269. Stocker R. October 2004. Antioxidant activities of bile pigments. Antioxid Redox Signal 6(5):841-849.
270. Storz P, Toker A. January 2, 2003. Protein kinase D mediates a stress-induced NFkappaB activation and survival pathway. EMBO J 22(1):109-120.
271. Stracke H, Hammes HP,WerkmannD,Mavrakis K, Bitsch I, Netzel M, Geyer J,Kopcke W, Sauerland C, Bretzel RG, Federlin KF. 2001. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes 109(6):330-336.
272. Stracke H, Lindemann A, Federlin K. 1996. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 104(4):311-316.
273. StrainWD, Chaturvedi N. December 2002. The renin-angiotensin-aldosterone system and the eye in diabetes. J Renin Angiotensin Aldosterone Syst 3(4):243-246.
274. Stroes ES, van Faassen EE, Yo M, Martasek P, Boer P, Govers R, Rabelink TJ. June 9, 2000. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 86(11):1129-1134.
275. Suh JH, Shenvi SV, Dixon BM, Liu H, Jaiswal AK, Liu RM, Hagen TM. March 9, 2004. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci U S A 101(10):3381-3386.
276. Suzen S, Buyukbingol E. August 2003. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr Med Chem 10(15):1329-1352.
277. Szabo C. July 2005. Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications. Pharmacol Res 52(1):60-71.
278. Szabo C, Biser A, Benko R, Bottinger E, Susztak K. November 2006. Poly(ADPribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice. Diabetes 55(11):3004-3012.
279. Takeuchi T, Jung EH, Nishino K, ItokawaY. 1990. The relationship between the thiamin pyrophosphate effect and the saturation status of the transketolase with its coenzyme in human erythrocytes. Int J Vitam Nutr Res 60(2):112-120.
280. Talior I, Tennenbaum T, Kuroki T, Eldar-Finkelman H. February 2005. PKC-deltadependent activation of oxidative stress in adipocytes of obese and insulin-resistant mice: Role for NADPH oxidase. Am J Physiol Endocrinol Metab 288(2):E405-E411.
281. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD. September 2000. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11(9):1656-1666.
282. Taubert D, Berkels R, Roesen R, KlausW. August 27, 2003. Chocolate and blood pressure in elderly individuals with isolated systolic hypertension. JAMA 290(8):1029-1030.
283. Tawakol A, Migrino RQ, Aziz KS, Waitkowska J, Holmvang G, Alpert NM, Muller JE, Fischman AJ, Gewirtz H. May 17, 2005. High-dose folic acid acutely improves coronary vasodilator function in patients with coronary artery disease. J Am Coll Cardiol 45(10):1580-1584.
284. Terry MJ, Maines MD, Lagarias JC. December 15, 1993. Inactivation of phytochromeand phycobiliprotein-chromophore precursors by rat liver biliverdin reductase. J Biol Chem 268(35):26099-26106.
285. Thomas MC, Baynes JW, Thorpe SR, Cooper ME. June 2005. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 6(4):453-474.
286. Timimi FK, Ting HH, Haley EA, Roddy MA, Ganz P, Creager MA. March 1, 1998. Vitamin C improves endothelium-dependent vasodilation in patients with insulindependent diabetes mellitus. J Am Coll Cardiol 31(3):552-557.
287. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. January 1, 1996. Vitamin C improves endothelium-dependent vasodilation in patients with noninsulin- dependent diabetes mellitus. J Clin Invest 97(1):22-28.
288. Tomas-Zapico C, Coto-Montes A. September 2005. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 39(2):99-104.
289. Tousoulis D, Antoniades C, Vasiliadou C, Kourtellaris P, Koniari K, Marinou K, Charakida M, Ntarladimas I, Siasos G, Stefanadis C. August 16, 2006. Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and inflammatory process, in patients with type 2 diabetes mellitus. Heart 93:244-246.
290. Tsuneki H, Ishizuka M, Terasawa M, Wu JB, Sasaoka T, Kimura I. August 26, 2004. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. BMC Pharmacol 4:18.
291. UK Prospective Diabetes Study (UKPDS) Group. 1998a. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837-853.
292. UK Prospective Diabetes Study (UKPDS) Group. 1998b. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) . Lancet 352(9131):854-865.
293. Valle I, Alvarez-Barrientos A, Arza E, Lamas S, Monsalve M. June 1, 2005. PGC- 1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res 66(3):562-573.
294. Van Etten RW, De Koning EJ, Verhaar MC, Gaillard CA, Rabelink TJ. June 2002. Impaired NO-dependent vasodilation in patients with Type II (non-insulindependent) diabetes mellitus is restored by acute administration of folate. Diabetologia JID - 0006777 45(7):1004-1010.
295. Vinson JA, Zhang J.May 4, 2005. Black and green teas equally inhibit diabetic cataracts in a streptozotocin-induced rat model of diabetes. J Agric Food Chem 53(9):3710-3713.
296. Vitek L, Jirsa M, Brodanova M, Kalab M, Marecek Z, Danzig V, Novotny L, Kotal P. February 2002. Gilbert syndrome and ischemic heart disease: A protective effect of elevated bilirubin levels. Atherosclerosis 160(2):449-456.
297. Vitek L, Novotny L, Sperl M, Holaj R, Spacil J. March 9, 2006. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis 21(5-6):408-414.
298. Vural H, Sabuncu T, Arslan SO, Aksoy N. October 2001. Melatonin inhibits lipid peroxidation and stimulates the antioxidant status of diabetic rats. J Pineal Res 31(3):193-198.
299. Wahlberg G, Carlson LA, Wasserman J, Ljungqvist A. November 1985. Protective effect of nicotinamide against nephropathy in diabetic rats. Diabetes Res 2(6):307-312.
300. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. May 2001. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280(5):E685-E694.
301. Wautier JL, Schmidt AM. August 6, 2004. Protein glycation: A firm link to endothelial cell dysfunction. Circ Res 95(3):233-238.
302. Way KJ, Katai N, King GL. December 2001. Protein kinase C and the development of diabetic vascular complications. Diabet Med 18(12):945-959.
303. Weidig P, McMaster D, Bayraktutan U. November 2004. High glucose mediates prooxidant and antioxidant enzyme activities in coronary endothelial cells. Diabetes Obes Metab 6(6):432-441.
304. Wheeler MD, Ikejema K, Enomoto N, Stacklewitz RF, Seabra V, Zhong Z, Yin M, Schemmer P, Rose ML, Rusyn I, Bradford B, Thurman RG. November 30, 1999. Glycine: A new anti-inflammatory immunonutrient. Cell Mol Life Sci 56(9-10):843-856.
305. WheelerMD, Thurman RG. November 1999. Production of superoxide and TNF-alpha from alveolar macrophages is blunted by glycine. Am J Physiol 277(5 Pt 1):L952-L959.
306. Williams ME. December 2004. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Curr Diab Rep 4(6):441-446.
307. Winiarska K, Fraczyk T, Malinska D, Drozak J, Bryla J. March 2006. Melatonin attenuates diabetes-induced oxidative stress in rabbits. J Pineal Res 40(2):168-176.
308. Winkler G, Pal B, Nagybeganyi E, Ory I, Porochnavec M, Kempler P. March 1999. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung 49(3):220-224.
309. Wolfram S, Raederstorff D, Preller M,Wang Y, Teixeira SR, Riegger C,Weber P. October 2006. Epigallocatechin gallate supplementation alleviates diabetes in rodents. J Nutr 136(10):2512-2518.
310. Wright CE, Lin TT, Lin YY, Sturman JA, Gaull GE. 1985. Taurine scavenges oxidized chlorine in biological systems. Prog Clin Biol Res 179:137-147.
311. Wu LY, Juan CC,Hwang LS, Hsu YP, Ho PH, Ho LT. April 2004. Green tea supplementation ameliorates insulin resistance and increases glucose transporter IV content in a fructose-fed rat model. Eur J Nutr 43(2):116-124.
312. Wu S, Ren J. February 13, 2006. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosci Lett 394(2):158-162.
313. Xia L, Wang H, Goldberg HJ, Munk S, Fantus IG, Whiteside CI. February 2006. Mesangial cell NADPH oxidase upregulation in high glucose is protein kinase C dependent and required for collagen IV expression. Am J Physiol Renal Physiol 290(2):F345-F356.
314. Yamabe N, Yokozawa T, Oya T, Kim M. October 2006. Therapeutic potential of (-)- epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. J Pharmacol Exp Ther 319(1):228-236.
315. Yamagishi S, Takeuchi M, Matsui T, Nakamura K, Imaizumi T, Inoue H. August 15, 2005. Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett 579(20):4265-4270.
316. Yamamoto Y, Yamagishi S, Yonekura H, Doi T, Tsuji H, Kato I, Takasawa S, Okamoto H, Abedin J, Tanaka N, Sakurai S, Migita H, Unoki H, Wang H, Zenda T, Wu PS, Segawa Y, Higashide T, Kawasaki K, Yamamoto H. May 2000. Roles of the AGE-RAGE system in vascular injury in diabetes. AnnNYAcad Sci 902:163-170.
317. Yamori Y, Nara Y, Ikeda K, Mizushima S. 1996. Is taurine a preventive nutritional factor of cardiovascular diseases or just a biological marker of nutrition? Adv Exp Med Biol 403:623-629.
318. Yano M, Hasegawa G, Ishii M,Yamasaki M, Fukui M, NakamuraN,Yoshikawa T. 2004. Short-term exposure of high glucose concentration induces generation of reactive oxygen species in endothelial cells: Implication for the oxidative stress associated with postprandial hyperglycemia. Redox Rep 9(2):111-116.
319. Yokozawa T, Nakagawa T, Oya T, Okubo T, Juneja LR. June 2005. Green tea polyphenols and dietary fibre protect against kidney damage in rats with diabetic nephropathy. J Pharm Pharmacol 57(6):773-780.
320. Yoshikawa M, Fujita H, Matoba N, Takenaka Y, Yamamoto T, Yamauchi R, Tsuruki H, Takahata K. 2000. Bioactive peptides derived from food proteins preventing lifestyle-related diseases. Biofactors 12(1-4):143-146.
321. Zeng XH, Zeng XJ, LiYY. July 15, 2003. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 92(2):173-176.
322. Zhang C, Yang J, Jennings LK. November 2004. Leukocyte-derived myeloperoxidase amplifies high-glucose-induced endothelial dysfunction through interaction with high-glucose-stimulated, vascular non-leukocyte-derived reactive oxygen species. Diabetes 53(11):2950-2959.
323. Zheng L, Szabo C,Kern TS.November 2004. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 53(11):2960-2967.
324. Zheng F, Zeng YJ, Plati AR, Elliot SJ, Berho M, Potier M, Striker LJ, Striker GE. August 2006. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int 70(3):507-514.
325. Ziegler D. 2004. Thioctic acid for patients with symptomatic diabetic polyneuropathy: A critical review. Treat Endocrinol 3(3):173-189.
326. Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schutte K, Kerum G, Malessa R. August 1999. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid:A7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 22(8):1296-1301.
327. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. February 2004. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A meta-analysis. Diabet Med 21(2):114-121.